LONDON, Aug 7 (Reuters) - Novo Nordisk on
Wednesday posted second-quarter operating profit below
expectations, raised its 2024 sales forecast but cut profit
outlook, as competition from Eli Lilly ( LLY ) in the booming
weight-loss drug market intensifies.